Johnson & Johnson is narrowing its focus again, nearly four years after peeling off its consumer health business .

The health care giant said Tuesday that it will separate its orthopedics business into a standalone company known as DePuy Synthes. The move leaves J&J focused on its pharmaceutical and MedTech segments, which make prescription drugs, contact lenses and technology to treat cardiovascular disease and help with surgeries.

Recommended Videos

The orthopedics business will be led by Namal Nawana, a former CEO of the medical technology business Smith & Nephew, which makes products for sports medicine and wound management and also focuses on orthopedics.

J&J’s orthopedics business pulled in more than $9 billion in sales last year. But the company said the split will help it foc

See Full Page